Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Advances and Challenges

Mikhail Konoplyannikov; Svetlana Kotova; Vladimir Baklaushev; Anatoly Konoplyannikov; Vladimir Kalsin; Peter Timashev; Alexander Troitskiy

doi:10.2174/1381612824666180913151059

Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Advances and Challenges

Curr Pharm Des. 2018;24(26):3132-3142. doi: 10.2174/1381612824666180913151059.

Authors

Mikhail Konoplyannikov^{1

2}, Svetlana Kotova^{1

2

3}, Vladimir Baklaushev², Anatoly Konoplyannikov⁴, Vladimir Kalsin², Peter Timashev^{1

3

5}, Alexander Troitskiy²

Affiliations

¹ Institute for Regenerative Medicine, Sechenov University, Moscow, Russian Federation.
² Federal Research Clinical Center of Specialized Medical Care and Medical Technologies of the FMBA of Russia, Moscow, Russian Federation.
³ N.N. Semenov Institute of Chemical Physics, Moscow, Russian Federation.
⁴ A. Tsyb Medical Radiological Research Center of the Ministry of Health of Russia, Obninsk, Russian Federation.
⁵ Institute of Photonic Technologies, Research center "Crystallography and Photonics", Troitsk, Moscow, Russian Federation.

PMID: 30209995
DOI: 10.2174/1381612824666180913151059

Abstract

Ischemic Heart Disease (IHD) has been recognized as the main cause of mortality in the modern world. Application of cell therapy technologies for the IHD treatment has been actively studied from the beginning of 2000s. The review is dedicated to the use of mesenchymal stem cells (MSC) in the therapy of IHD. The strategies of the MSC modification in vitro for improvement of their regenerative potential are extensively discussed, including preconditioning to enhance the cell survival, boosting their paracrine effect and manipulating their cardiomyogenic differentiation. The optimization of the MSC delivery and opportunities related to the use of biomaterials as cell carriers are also discussed. The results of the most important clinical studies on the MSC-based IHD therapy are presented, including those completed and published in the literature and the ongoing clinical trials registered at clinicaltrials.gov by June 2018.

Keywords: Ischemic heart disease; MSC-based IHD; cell therapy; clinical trials; mesenchymal stem cells; regenerative medicine..

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Humans
Mesenchymal Stem Cell Transplantation*
Mesenchymal Stem Cells / cytology*
Myocardial Ischemia / therapy*